SI3494115T1 - Derivati N-(fenilsulfonil)benzamida kot BCL-2 inhibitorji - Google Patents
Derivati N-(fenilsulfonil)benzamida kot BCL-2 inhibitorjiInfo
- Publication number
- SI3494115T1 SI3494115T1 SI201730535T SI201730535T SI3494115T1 SI 3494115 T1 SI3494115 T1 SI 3494115T1 SI 201730535 T SI201730535 T SI 201730535T SI 201730535 T SI201730535 T SI 201730535T SI 3494115 T1 SI3494115 T1 SI 3494115T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phenylsulfonyl
- bcl
- inhibitors
- benzamide derivatives
- benzamide
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- ZBGWAJQUDSCDPB-UHFFFAOYSA-N n-(benzenesulfonyl)benzamide Chemical class C=1C=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1 ZBGWAJQUDSCDPB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371504P | 2016-08-05 | 2016-08-05 | |
| US201762454101P | 2017-02-03 | 2017-02-03 | |
| PCT/US2017/045428 WO2018027097A1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| EP17754889.8A EP3494115B1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3494115T1 true SI3494115T1 (sl) | 2021-02-26 |
Family
ID=59677319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730535T SI3494115T1 (sl) | 2016-08-05 | 2017-08-04 | Derivati N-(fenilsulfonil)benzamida kot BCL-2 inhibitorji |
Country Status (27)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156398A1 (en) * | 2016-03-10 | 2017-09-14 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| CA3031419C (en) * | 2016-08-05 | 2021-08-24 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| AU2018255621B2 (en) | 2017-04-18 | 2022-03-10 | Fochon Pharmaceuticals, Ltd. | Apoptosis-inducing agents |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| MX2020009759A (es) * | 2018-07-31 | 2020-10-08 | Ascentage Pharma Suzhou Co Ltd | Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop. |
| JP7058345B2 (ja) * | 2018-07-31 | 2022-04-21 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用 |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| WO2020024834A1 (en) * | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| AU2019385458A1 (en) * | 2018-11-23 | 2021-01-07 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and use thereof |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| AU2020321068A1 (en) * | 2019-07-31 | 2021-03-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| US12287338B2 (en) | 2019-11-27 | 2025-04-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway |
| US12343352B2 (en) | 2019-12-03 | 2025-07-01 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors |
| US20220323465A1 (en) * | 2019-12-04 | 2022-10-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| MX2022006631A (es) | 2019-12-06 | 2022-09-07 | Loxo Oncology Inc | Dosificacion de un inhibidor de la tirosina cinasa de bruton. |
| CN113354636B (zh) * | 2020-03-06 | 2022-08-09 | 苏州亚盛药业有限公司 | N-(苯基磺酰基)苯甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式 |
| WO2021180040A1 (zh) * | 2020-03-12 | 2021-09-16 | 南京明德新药研发有限公司 | 苯并五元环类化合物 |
| TW202200574A (zh) | 2020-04-15 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Bcl-2抑制劑 |
| WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
| CN113880834B (zh) * | 2020-07-01 | 2023-01-20 | 苏州亚盛药业有限公司 | N-(苯基磺酰基)苯甲酰胺类化合物及其中间体的合成方法 |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| CA3184959A1 (en) * | 2020-07-10 | 2022-01-13 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfonylbenzamide derivative and conjugate thereof, preparation method therefor and use thereof |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| JP2023539114A (ja) * | 2020-08-21 | 2023-09-13 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 全身性エリテマトーデスを治療する組成物及び方法 |
| CN114073703B (zh) * | 2020-08-21 | 2022-12-30 | 苏州亚盛药业有限公司 | 用于治疗非酒精性脂肪肝炎的组合物和方法 |
| WO2022111558A1 (en) * | 2020-11-25 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof |
| WO2022143602A1 (en) * | 2020-12-28 | 2022-07-07 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods of treating multiple sclerosis |
| CN114835704B (zh) * | 2021-02-01 | 2023-10-27 | 苏州亚盛药业有限公司 | 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 |
| EP4319800A1 (en) | 2021-04-07 | 2024-02-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| EP4382126A4 (en) | 2021-08-02 | 2025-07-30 | Ascentage Pharma Suzhou Co Ltd | PHARMACEUTICAL COMBINATION AND ITS USE |
| WO2023104043A1 (zh) * | 2021-12-06 | 2023-06-15 | 杭州和正医药有限公司 | 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| EP4421075A1 (en) * | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
| CN121175043A (zh) | 2023-03-03 | 2025-12-19 | 伊昂克图拉股份有限公司 | 用于治疗血液恶性肿瘤的罗吉诺利西布与bcl-2抑制剂的组合 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| CN101534904B (zh) | 2006-09-05 | 2013-11-06 | Abbvie公司 | 治疗血小板过量的bcl抑制剂 |
| WO2008070663A2 (en) | 2006-12-04 | 2008-06-12 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| KR101692705B1 (ko) | 2008-12-05 | 2017-01-04 | 애브비 인코포레이티드 | 암 및 면역 질환의 치료를 위한 Ｂｃｌ２선택적 아폽토시스-유도제로서의 설폰아미드 유도체 |
| RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| WO2010093742A1 (en) | 2009-02-11 | 2010-08-19 | Abbott Laboratories | Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PL2435432T6 (pl) | 2009-05-26 | 2024-02-12 | Abbvie Ireland Unlimited Company | Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| CA3152557A1 (en) * | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UY33746A (es) | 2010-11-23 | 2012-06-29 | Abbott Lab | Método de tratamiento que usa inhibidores selectivos de bcl-2 |
| SI2643322T1 (en) * | 2010-11-23 | 2018-01-31 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| US10327687B2 (en) | 2015-12-30 | 2019-06-25 | Dexcom, Inc. | System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors |
| CA3031419C (en) | 2016-08-05 | 2021-08-24 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
-
2017
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en not_active Ceased
- 2017-08-04 SM SM20210025T patent/SMT202100025T1/it unknown
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active Active
- 2017-08-04 HR HRP20202073TT patent/HRP20202073T1/hr unknown
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active Active
- 2017-08-04 MY MYPI2019000239A patent/MY199409A/en unknown
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 MX MX2019001391A patent/MX381588B/es unknown
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282099B (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl–2 inhibitors | |
| IL272910A (en) | Ectonucleotide pyrophosphate-phosphodiesterase 1 (ENPP-1) inhibitors and their uses | |
| LT3788042T (lt) | Bcl-2 inhibitoriai | |
| DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
| IL263739B (en) | History of n-(converted-phenyl)-sulfonamide as kinase inhibitors | |
| DK3328849T3 (da) | 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer | |
| DK3672976T3 (da) | Bcl-2-hæmmere | |
| EP4051676A4 (en) | BCL-2 INHIBITORS | |
| DK3442947T3 (da) | Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere | |
| DK3440076T3 (da) | Heterocykliske amider, der kan anvendes som proteinmodulatorer | |
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| HUE058009T2 (hu) | 1,3-Tiazol-2-il szubsztituált benzamid-származékok | |
| DK3105218T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3105226T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3313833T3 (da) | Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| DK3724196T3 (da) | Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3126354T3 (da) | Halogenerede quinazolin-thf-aminer som pde1-inhibitorer | |
| DK3319970T3 (da) | Pyrido-oxazinonderivater som tnap-hæmmere | |
| DK3712162T3 (da) | Smac-mimetica anvendt som iap-inhibitorer og anvendelse deraf | |
| DK3277682T3 (da) | 6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere | |
| DK3551634T3 (da) | Substituerede pyrazoloazepin-8-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3551633T3 (da) | Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| ZA202002786B (en) | Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors | |
| MA41557A (fr) | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |